Current Use and Promise of Urinary Markers for Urothelial Cancer.
Curr Urol Rep
; 19(12): 96, 2018 Oct 17.
Article
en En
| MEDLINE
| ID: mdl-30328534
ABSTRACT
PURPOSE OF REVIEW We summarize the current literature regarding the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS:
Four urinary biomarkers have FDA approval for the detection of bladder cancer; however, they have not supplanted cystoscopy and urine cytology as the gold standard. Recent technological advances in next-generation sequencing have allowed the field of urinary biomarker research to move beyond protein biomarkers and now include genomic, transcriptomic, and epigenetic panels. The search for a noninvasive, inexpensive urinary biomarker for the detection of bladder cancer that can replace cystoscopy and cytology continues. There are several promising genomic, transcriptomic, and epigenetic marker panels in development; however, these new tests require further prospective validation before widespread clinical implementation.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Vejiga Urinaria
/
Carcinoma de Células Transicionales
/
Biomarcadores de Tumor
Límite:
Humans
Idioma:
En
Revista:
Curr Urol Rep
Asunto de la revista:
UROLOGIA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos